Valuation: Tectonic Therapeutic, Inc.

Market Cap 411M 375M 347M 314M 589M 38.41B 616M 4.19B 1.66B 20.76B 1.54B 1.51B 65.76B P/E 2026 *
-4.34x
P/E 2027 * -3.96x
Enterprise Value 200M 182M 169M 153M 287M 18.7B 300M 2.04B 810M 10.1B 751M 735M 32.01B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
63.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.54%
1 week-0.71%
Current month+6.12%
1 month-3.83%
3 months-41.78%
6 months-27.22%
Current year+0.62%
1 week 19.76
Extreme 19.76
21.57
1 month 18.54
Extreme 18.535
22.8
Current year 16.77
Extreme 16.77
39.53
1 year 16.77
Extreme 16.77
39.53
3 years 13.7
Extreme 13.7
61.07
5 years 13.7
Extreme 13.7
61.07
10 years 13.7
Extreme 13.7
61.07
Date Insider Type Main position Quantity % Market Cap. Importance
10/26/26 Exercice

Chief Executive Officer

20,000 0.1023%
9/30/26 Sell

Chief Technology Officer

-536 0.0027%
9/25/26 Tax

Chief Technology Officer

-525 0.0027%
Change 5-day change 1-year change 3-year change Capi.($)
-1.21%-0.71%+16.22% - 411M
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-2.91%+6.20%+89.22% 58.91B
-2.05%-1.95%+23.21%+82.81% 55.24B
-0.78%-4.78%+13.55%+111.10% 45.66B
-0.71%-6.04%+14.74%+21.35% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+2.36%-4.84%+134.62%+654.49% 34.48B
-0.80%+0.61%+77.26%+56.26% 32.5B
+0.83%+20.41%-26.92%+492.57% 31.69B
Average -0.66%-0.59%+33.08%+179.75% 40B
Weighted average by Cap. -0.81%-1.28%+33.02%+153.48%

Financials

2026 *2027 *
Net sales - -
Net income -95.21M -86.74M -80.3M -72.63M -136M -8.89B -143M -971M -385M -4.8B -357M -350M -15.22B -131M -119M -110M -99.78M -187M -12.22B -196M -1.33B -529M -6.6B -491M -480M -20.91B
Net Debt -211M -192M -178M -161M -302M -19.72B -316M -2.15B -854M -10.65B -792M -775M -33.75B -392M -357M -331M -299M -561M -36.6B -587M -4B -1.58B -19.78B -1.47B -1.44B -62.65B
Projected Income Statement - Annual - Tectonic Therapeutic, Inc.
Logo Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Its product candidates are TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Its second development candidate, TX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (APLNR), also known as the apelin receptor. Its APJ is a differentiated approach for the treatment of hereditary hemorrhagic telangiectasia (HHT) and is a selective anti-angiogenic target that is primarily expressed in endothelial cells.
Employees
60
Date Price Change Volume
26-11-20 US$20.99 -0.24% 117,694
26-11-19 US$21.04 0.00% 87,174
26-11-18 US$21.04 +4.78% 169,440
26-11-17 US$20.08 -4.29% 144,258
26-11-16 US$20.98 -0.76% 237,430
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Tectonic Therapeutic, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.04USD
Average target price
71.00USD
Spread / Average Target
+237.45%
  1. Stock Market
  2. Stocks
  3. TECX Stock